A novel immunocompetent murine model for replicating oncolytic adenoviral therapy

@article{Zhang2015ANI,
  title={A novel immunocompetent murine model for replicating oncolytic adenoviral therapy},
  author={L. Zhang and F. Hedjran and C. Larson and G. L. Perez and T. Reid},
  journal={Cancer Gene Therapy},
  year={2015},
  volume={22},
  pages={17 - 22}
}
Oncolytic adenoviruses are under investigation as a promising novel strategy for cancer immunotherapeutics. Unfortunately, there is no immunocompetent mouse cancer model to test oncolytic adenovirus because murine cancer cells are generally unable to produce infectious viral progeny from human adenoviruses. We find that the murine K-ras-induced lung adenocarcinoma cell line ADS-12 supports adenoviral infection and generates infectious viral progeny. ADS-12 cells express the coxsackie and… Expand
Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis
TLDR
Results showed, for the first time, that TMZ could render murine tumor cells more susceptible to oncolytic virotherapy. Expand
Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model
TLDR
Results indicate that repeated whole cell vaccination using an oncolytic adenovirus may be a potent approach to evoke immunogenic cell death. Expand
Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses
TLDR
Recent advances in adenovirus-based oncolytic therapies targeting ovarian cancer and recent advances in mapping immune responses to on colytic virus therapies in ovarian cancer are covered. Expand
Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents
TLDR
The use of the murine syngeneic immunocompetent ID8 ovarian cancer model enables the rational design of oncolytic agents to achieve anti-tumor immunotherapy, and limits of widely employed murine xenograft models of ovarian cancer limit their utility for design and study of armed CRAd virotherapy agents. Expand
Chemovirotherapy of Lung Squamous Cell Carcinoma by Combining Oncolytic Adenovirus With Gemcitabine
TLDR
The combined application of Ad- VT and gemcitabine has a synergistic effect, which can increase the anti-tumor effect and reduce the toxicity of chemotherapy drugs, indicating that Ad-VT has a potential clinical value in the treatment of lung squamous cell carcinoma. Expand
Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives
TLDR
Current methods to test OAd efficacy in vitro and in vivo and the development of new model systems to test both on colysis and immune stimulatory components of oncolytic adenovirotherapy are focused on. Expand
Drug development against human adenoviruses and its advancement by Syrian hamster models.
TLDR
The availability of an animal model confirmed the activity of some drugs already in clinical use while proving that others are inactive, and led to the identification of several lead compounds that await further development. Expand
Adenovirus Lacking E1b Efficiently Induces Cytopathic Effect in HPV-16-Positive Murine Cancer Cells via Virus Replication and Apoptosis
TLDR
The results suggest that TC-1 murine cancer cells allow Adhz60 replication and oncolysis, and that HPV16 E7 open reading frame encodes functions analogous to these deleted adenovirus E1 proteins. Expand
CRAd with capsid incorporated mesothelin for higher anti-tumor immunization
TLDR
This project combined the two earlier mentioned strategies to design a vaccine for ovarian cancer, with the hypothesis that CRAd with capsid-incorporated mesothelin gives higher anti-tumor immunization then single treatment of CRAd or mesothelins as a transgene. Expand
Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.
TLDR
The challenges of adenovirus-based oncolytic therapies targeting ovarian cancer are highlighted and recent advances to improve their potential in combination with immunotherapies are outlined. Expand
...
1
2
...

References

SHOWING 1-10 OF 36 REFERENCES
Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
TLDR
The findings show that the Syrian hamster is a promising immunocompetent model that is permissive to human adenovirus replication in tumors as well as normal tissues and may become a valuable tool for the field of oncolytic adenvirus vectors in which vector safety and efficacy can be evaluated. Expand
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.
  • G. Halldén, R. Hill, +6 authors D. Kirn
  • Biology, Medicine
  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2003
TLDR
Surprisingly, productive viral replication was demonstrated in several lines; replication varied from levels similar to those for some human carcinoma lines (e.g., CMT-64) to very low levels. Expand
Cotton rat tumor model for the evaluation of oncolytic adenoviruses.
TLDR
It is shown that the cotton cancer rat cell line LCRT supports the replication of human Ad in tissue culture and that the cells are destroyed on virus replication, and the cotton rat can be used as an animal model to evaluate oncolytic Ad vectors. Expand
Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.
TLDR
The effect observed with the different cotton rat tumor cell lines mimics the variable results of human clinical trials highlighting the potential relevance of this model for assessing the activity and toxicity of oncolytic adenoviruses. Expand
Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.
TLDR
This chapter describes the maintenance of these Syrian hamster cell lines in culture and how to assess oncolytic Ad vector replication in these cells in vitro and describesHow to assess replication in normal tissues such as the lungs and gives helpful tips on handling, anesthesia, and general care of Syrian hamsters. Expand
Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters.
TLDR
Determination of cytopathic effect, viral spread, progeny production, and the expression of late viral proteins indicates that the complete viral cycle of adenovirus takes place, albeit less efficiently than in highly permissive human cancer cell lines A549 and HuH7. Expand
A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy
TLDR
This study provided a novel immunocompetent animal model which is useful for evaluating RCAd infectability, cytopathy, and replication, and the combined use of RCAd and RDAd provided a new solution for cancer gene therapy. Expand
Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase
TLDR
Results indicate that combination of fiber-modified vectors and a HSVtk/GCV system is a potentially useful and safe approach for the treatment of tumors lacking CAR expression, and that fiber- modified vectors could be of great utility for gene therapy and gene transfer experiments. Expand
INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies
TLDR
The results underscore the utility of the Syrian hamster as a permissive immunocompetent model for Ad5 pathogenesis and oncolytic Ad vectors. Expand
Replication Properties of Human Adenovirus In Vivo and in Cultures of Primary Cells from Different Animal Species
TLDR
The data strongly suggest that infection of swine with human adenovirus or oncolyticadenoviral vectors is a more appropriate animal model to study adenOViral pathogenicity or pharmacodynamic and toxicity profiles of adenviral vectors than infection of mice. Expand
...
1
2
3
4
...